Pharmacogenomics is the study of how genetic variation can affect medication response, metabolism, transport, or adverse-effect risk.
Why it matters for supplement contexts
Supplement logging often happens beside prescription or over-the-counter medication use. A pharmacogenomic result may help explain why a medication is handled differently, and that can change how cautiously a supplement stack should be reviewed for interaction risk.
What the result can say
A result may describe likely enzyme activity, transporter activity, or response category for a specific medication-gene pair. It is strongest when the gene, medication, population, and outcome have been studied directly. It is weaker when stretched into general claims about wellness products or broad metabolism.
What the result cannot do
Pharmacogenomics does not replace a pharmacist, prescriber, label warning, or interaction check. It also does not turn a supplement recommendation into a medication plan. Any medication-facing finding belongs inside the same risk checks that protect stack decisions from unsafe overlap.
Relation to CYP enzymes
Many pharmacogenomic reports include CYP450 enzyme genes because those enzymes help metabolize many drugs. Enzyme context can matter, but dose changes and medication decisions are clinical actions, not app-level recommendations.
How this appears in Unfair
Unfair can use pharmacogenomic context to make explanations more careful, lower confidence where interaction uncertainty is high, or prompt a user to confirm medication details before ranking. It should not autonomously change medication guidance.
Safety note
Medication-related genetic findings should be reviewed with a clinician or pharmacist, especially when a user is taking psychiatric, cardiovascular, anticoagulant, transplant, seizure, or hormone-related medications.